PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.16%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
23.98%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
7.46%
Other expenses growth 0-10% reflects moderate increase. Benjamin Graham would investigate nature of expenses.
15.26%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
15.26%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
-36.68%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
7.46%
D&A growth 5-10% suggests significant asset additions. Howard Marks would investigate investment returns.
-50.67%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-15.26%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-81.62%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-50.43%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-36.68%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-50.43%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-43.14%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-43.14%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
5.01%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
5.01%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.